TrueBeam™ – Your tool for SABR.

Stereotactic Ablative Radiotherapy (SABR) requires the highest possible precision – TrueBeam™ delivers it. Patients want to be treated in a short time – TrueBeam delivers it.

The Varian TrueBeam system with its unique high intensity modes in combination with the RapidArc® delivery technique enables you to deliver Stereotactic Ablative Radiotherapy with doses up to 25 Gy in 2 minutes – a delivery time you couldn’t imagine before.

The flexible fully integrated imaging system of the TrueBeam system provides you with the confidence that the dose is precisely delivered to the planned position, while the integration with the Aria oncology information system and the Eclipse™ treatment planning system takes care that you have all information – plans, images and more – ready at your fingertips whenever you need them.

Be Smart with your patients, use TrueBeam.

---

CME ACCREDITATION

The conference organisers have applied for CME Accreditation with the Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME).

DEADLINES

Abstract submission deadline: 7 December 2012
Early registration: 12 December 2012
Late registration: 18 March 2013
Desk registration: as of 19 March 2013
Introduction

2nd ESTRO FORUM

It is our pleasure to invite you to attend the 2nd ESTRO Forum in Geneva, Switzerland from 19-23 April 2013. Built on the success of the London Anniversary in 2011, the ESTRO Forum is following the concept of gathering several meetings reflecting the various aspects of the radiation oncology arena. The Clinical & Translational meeting, the GEC-ESTRO-ISORT meeting, the Physics Biennial meeting, the RTT meeting, and the PREVENT (Prediction, Recognition, Evaluation and Eradication of Normal Tissue effects of radiotherapy) meeting will altogether foster interdisciplinarity and exchanges between professionals of radiotherapy.

The ESTRO Forum will offer the usual broad portfolio of scientific and educational opportunities in line with the ESTRO Vision, which aims at developing optimal patient care and equitable patient access to state-of-the-art radiation therapy. In this framework, the meeting will provide symposia, presidential and joint sessions, teaching lectures and debates. It will also be a further opportunity for young professionals to meet, learn, and deepen their engagement within the society. Finally, the ESTRO Forum will also be the biggest platform in Europe at which to discover the latest innovations of the industry.

The scientific experts of the five meetings have compiled an outstanding scientific programme dedicated to clinicians, medical physicists, biologists, radiation technologists and nurses, in collaboration with non-European societies. The delegates will meet in this thrilling environment and share their knowledge for the benefit of their patients.

We look forward to meeting you in the unique atmosphere of welcome and friendship presented at all ESTRO meetings, enriched by the international tradition of Geneva.

With warm regards,

Vincenzo Valentini
Chairperson, Scientific Programme Committee of 2nd ESTRO Forum

Welcome Letters

CLINICAL & TRANSLATIONAL MEETING

ESTRO would like to welcome all Forum delegates to the dedicated Clinical & Translational programme and especially to the new and expanded interdisciplinary tracks that have been selected to appeal to all disciplines involved in modern radiation oncology practice. Symposia within the clinical track will include ‘state of the art’ updates and debates in a number of rapidly changing areas, including:

• New areas where organ preservation is a goal of radiation therapy,
• Dose optimisation in prostate cancer radiotherapy,
• The scope for treatment individualisation with head and neck radiotherapy,
• Optimal approaches to loco-regional control in breast cancer,
• The role of radiotherapy in the management of upper GI malignancies,
• The changing role of radiotherapy in the management of Hodgkin’s & Non-Hodgkin’s lymphoma,
• Treatment intensification for NSCLC.

The 2nd Forum has prioritised an extended interdisciplinary programme which will address strategic interdisciplinary developments in radiation oncology, including:

• The impact and research opportunities arising from the Horizon 2020 project,
• The significance of high-throughput ‘omics’ technologies to new clinical trials and clinical practice,
• The potential role of nano-technology to imaging and therapeutics in radiation oncology,
• New developments and challenges in quality assurance, clinical audit and quality systems,
• The state of the art and future of proton and hadron therapies.

The Clinical and Translational Group of Experts looks forward to welcoming all radiation oncology professionals to this very exciting programme.

Donal Hollywood
Chairperson of the Clinical & Translational Meeting

PHYSICS BIENNIAL MEETING

Organised within the frame of the 2nd ESTRO Forum, the physics tracks will take place alongside scientific tracks originating from other members of our ESTRO ‘family’. It is indeed our belief that this construction both preserves the need of the physics community to have a dedicated conference while at the same time it allows for essential interactions within and beyond our field.

The Biennial Physics Meeting programme will provide opportunities for exploring new achievements and challenges in radiophysics physics research whilst also offering a series of high-level teaching lectures. The many scientific symposia will be covering key issues such as functional imaging, image-guided and adaptive therapy as well as proton and particle therapy.

In addition, several of the interdisciplinary tracks will be highly relevant for radiotherapy physicists giving plenty of opportunities for scientific interactions between disciplines, a true hallmark of the ESTRO conferences. They will include for example a ‘radiotherapy horizon scanning’ day, covering the future challenges of medical physics in keeping our profession an active clinical and academic specialty.
Welcome Letters

On behalf of the Physics Track Experts, it is therefore my great pleasure to invite you to attend and take active part in the Biennial Physics Meeting taking place in the beautiful, global city of Geneva, a city closely associated with physics and science.

Ludwig Paul Muren
Chairperson of the Biennial Physics Meeting

RTT MEETING

Within this comprehensive scientific forum, I would like to highlight the RTT programme which will start with a pre-meeting dedicated to Radiobiology, focusing on basic principles and on selected aspects relevant for the daily practice of RTTs. The symposia themes will be about:

- Improving treatment accuracy (new challenges in positioning, immobilisation and verification),
- Advanced practice for RTTs,
- Research on geometric uncertainties,
- The generation of new imaging modalities with a focus on functional and molecular imaging,
- Treatment reproducibility, multidisciplinary aspects of modern brachytherapy care in collaboration with the GEC-ESTRO group,
- The role of “new tools” in the education of RTTs in light of the new core curriculum,
- State of the art in the delineation of normal structures with added contouring workshops and a debate on this major issue.

We hope to receive many abstracts on these topics from you to enhance this rich and interesting scientific programme and to further share and develop our knowledge, know-how and experience.

Danilo Pasini
Chairperson of the RTT meeting

GEC-ESTRO-ISIORT MEETING

On behalf of the brachytherapy community in ESTRO represented by the GEC-ESTRO group, I would like to welcome you to this forum incorporating the annual GEC-ESTRO and ISIORT (International Society of Intraoperative Radiation Therapy) meetings. Within the GEC-ESTRO meeting you will find an exciting programme covering all aspects of modern brachytherapy. The pre-meeting symposium will address the question of focal therapy for localised prostate cancer with particular emphasis on the role of brachytherapy, an important emerging change in the management of prostate cancer in which brachytherapy will have a major role. The following two days will see an exciting programme of teaching lectures, seminars and debates covering head and neck, anal and gynaecological cancers alongside more controversial generic issues such as the importance of imaging and consideration of integral doses in brachytherapy. Prffered paper sessions also feature strongly and we encourage you to submit abstracts from your current work to enhance this aspect of the meeting.

Peter Hoskin
Chairperson of the GEC-ESTRO-ISIORT Europe meeting

Within this forum, we aim to capture the spirit of previous GEC-ESTRO meetings to provide an environment where the brachytherapy community can interact, discuss and dispute the important issues in modern brachytherapy.

We look forward to receiving your abstracts and welcoming you to these exciting few days devoted to brachytherapy.

Peter Hoskin
Chairperson of the GEC-ESTRO-ISIORT Europe meeting

PREVENT MEETING

Prediction, Recognition, Evaluation and Eradication of Normal Tissue effects of radiotherapy

On behalf of the PREVENT Scientific Group of Experts, we are pleased to invite you to participate in a two-day conference focusing on selected aspects of radiation adverse effects in normal tissues. The conference aims to bring together physics, biological, epidemiological and clinical approaches to quantifying radiation injury, understanding mechanisms and developing strategies for reducing this damage. The structure of the conference will involve teaching lectures, symposia with plenary lectures addressing related topics, followed by proffered papers.

There will be ample time for informal discussion with the aim of facilitating collaborations that might lead to new research initiatives. Topics that are not included in the formal programme can be discussed during poster presentations.

Themes that will be formally covered include:

- Molecular epidemiology/dosimetry (population based approaches on large cohorts),
- Individualized treatment (dose-volume and imaging, comorbidity, and genetics),
- Fibrosis (early bio-markers and clinical trials),
- Regenerative therapy (stem cell based approaches and paracrine stimulation).

We look forward to welcoming you in Geneva.

Marie-Catherine Vazelin & Jan Alsner
Chairpersons of the PREVENT meeting
Committees

2nd ESTRO Forum Scientific Programme Committee
Chair: V. Valentini (IT)
Members: J. Alsner (DK), J. Bourhis (FR), D. Hollywood (IE), P. Hoskin (UK), R. Mirabelli (CH), R. Moeckli (CH), L. Muren (DK), D. Pasini (IT), M.C. Vozenin (FR).

Biennial Physics Meeting Experts
Chair: L. Muren (DK)

Clinical & Interdisciplinary Meeting Experts
Chair: D. Hollywood (IE)
Members: C. Belka (DE), J. Borras (ES), E. Deutsch (FR), C. Grau (DK), V. Grégoire (BE), K. Haustermans (BE), J. Jaal (EE), B. Jereczek (IT), V. Kwo (UK), Y. Lievens (BE), A.H. Ree (NL), M. Verheij (NL), D. Zips (DE).

Young Track Experts
Chair: A.R. Filippi (IT), E. Malinen (NO)
Members: M. Boerma (US), C. Clark (UK), B. Eberle (CH), E. Gerolimenas (EE), P. Kelly (IE), M. Leech (IE), M. Mangioni (IT), P. Moura (PT), S. Rivera (FR).

RTT Meeting Experts
Chair: D. Pasini (IT)
Members: A. Bajen (DK), M. Kamphuis (NL), V. Karadza (HR), M. Leech (IE), M. Mast (NL), A. Osztavics (AT), A. Vaandering (BE).

GEC-ESTRO Meeting Experts
Chair: P. Hoskin (UK)
Members: C. Haie-Meder (FR), G. Kovács (DE), J. Lindegaard (DK), C. Polgar (HU), H. Rutten (NL), F. Sedlmayer (AT), F.A. Siebert (DE), E. Van Limbergen (BE).

ISIORT Europe Meeting Experts
Chair: H. Rutten (NL)
Members: F. Calvo (ES), A. Ciaibattoni (IT), C. Haie-Meder (FR), C. Herskind (DE), P. Hoskin (UK), M. Krengli (IT), H. Marsiglia (FR), R. Orecchia (IT), F. Sedlmayer (AT), V. Valentini (IT), F. Wenz (DE).

PreVent Meeting Experts
Chair: J. Alsner (DK), M.C. Vozenin (FR)
Members: R. Coppers (NL), S. Darby (UK), D. de Ruysscher (NL), W. Dör (AT), J. Hall (FR), L. Muren (DK), F. Stewart (NL), J. Yarnold (UK).

National Organising Committee
Honorary Chair: J. Bernier (CH)
Chair: R. Mirabelli (CH), R. Moeckli (CH)
Members: D.M. Aebersold (CH), S. Bodis (CH), U. Dechantsreiter (CH), G. Dipasquale (CH), J.C. Horiot (CH), S. Küss (CH), T. Laman (CH), P. Marsier (CH), O. Matzinger (CH), B. Petoors (CH), G.A. Pesce (CH), J.Y. Ray (CH), U. Schneider (CH), P. Thum (CH), D.C. Weber (CH), K. Zaugg (CH), F. Zimmermann (CH).
**PHYSICS PRE-MEETING COURSE**
Challenges of dose verification for new techniques and technologies in external x-ray beam radiotherapy

- **Friday, 19 April 2013**
- Course Directors: N. Jornet (ES) and G. Kragl (AT)

**COURSE AIMS**
A large variety of new treatment units such as Cyberknife, Tomotherapy, flattening filter free linacs, Vero as well as advanced application techniques such as IMRT, SBRT, tracking and gating challenge the standard dose verification methods. In addition, the clinical implementation of the novel techniques also puts high demands on radiotherapy staff as it requires a careful revision of QC procedures with a wise and cost-effective use of resources without compromising safety and/or diminishing quality.

This course aims at reviewing the suitability of commercial detectors and dosimetry methods for reference and relative dose measurements for new equipment and techniques. Methods for data comparison and also for data interpretation will be reviewed. Commissioning, patient related dose verifications (pre-treatment and in vivo) and TPS performance assessment will be discussed. The participants will be provided with information helping to process and critically analyse verification results.

**WHO SHOULD ATTEND?**
This course is aimed primarily at medical physicists and medical physicists in training, and at radiation technologists performing or intending to perform dosimetric quality controls for advanced treatment modalities.

**LEARNING OBJECTIVES**
- Update on detectors for dose measurement in novel techniques.
- Review the application of reference dosimetry protocols for new equipment where standard reference conditions cannot be set.
- Know advantages and limitations of the different commercially available dosimetry systems.
- Be able to choose the most appropriate detector to perform accurate measurements in non-standard irradiation conditions.
- Get familiar with different methods for data comparison.
- Be able to critically interpret measured data.
- Be prepared to design dosimetry tests sensible enough to detect discrepancies between the planned and delivered dose for new techniques and/or technologies.
- Provide know-how to assess the performance of a TPS (general or specific purpose) for new techniques.
- Review methods for pre-treatment dose verification and in vivo dose verification.

---

**PHYSICS PRE-MEETING COURSE**
Statistics for radiotherapy data

- **Friday, 19 April 2013**
- Course Directors: D. Verellen (BE) and T. Rancati (IT)

**COURSE AIMS**
- Presentation of statistical methods that can be used in radiotherapy data analysis.
- Analysis of the assumptions behind statistical methods and identification of the appropriate tools for a given dataset.
- Ability of evaluating clinical models, with special focus on variable selection, estimates of uncertainties and model validation.

**WHO SHOULD ATTEND?**
The course is aimed at professionals in radiotherapy, specifically radiation oncologists and medical physicists.

**CONTENT**
- Clinical trials and evidence-based medicine,
- Parametric and non-parametric statistics,
- Logistic regression,
- Survival analysis and Cox proportional hazards,
- Parameter estimation,
- Clinical prediction models,
- Meta-analysis and meta-regression,
- Introduction to Artificial Neural Networks.

---

**RTT PRE-MEETING COURSE**
Applied radiobiology in daily clinical routine

- **Friday, 19 April 2013**
- Course Directors: A. Ostavicz (AT) and W. Dörr (AT)

**COURSE AIMS**
The aim is to provide an introduction of radiation biology as applied to radiotherapy. It will cover the basic mechanisms of the radiation response of normal tissues and tumours to clinical treatments protocols. The biological basis of tissue tolerance will be exemplified. Current (radio)biology-based approaches for the improvement of the outcome of radio oncological therapies will be described, including altered fractionation schemes, implementation of dose-volume constraints modification of hypoxia, combined radiotherapy/chemotherapy and biologically targeted strategies.

Following the course, participants should have a better understanding of the biological reasons for different fractionation schedules, the rationale for individually planned dose distributions, and novel combined treatment protocols, aiming at the most effective and less toxic schedule for the patients in their treatment units.
Pre-Meeting Courses

WHO SHOULD ATTEND
The course is designed for RTTs who have to organise the daily treatments of the patients, in order to improve - on a scientific basis - their response to unexpected treatment interruptions, e.g. after machine breakdowns or no show of patients in the clinical routine. It is also relevant for trainees in radiotherapy and radiation oncologists who want to update their knowledge, as well as medical physicists who wish to familiarise themselves within this field. Lectures and practical sessions (case discussions) are constructed in a way that little or no classical radiobiology background is required.

CONTENT
A series of basic lectures introducing clinical radiobiology,
• Mechanisms and models of tumour and normal tissue effects of radiotherapy,
• Tumour response to radiotherapy and the relevance of tumour hypoxia,
• Linear-quadratic modelling of fractionation effects,
• Alternative fractionation schedules in radiotherapy,
• Combined radiotherapy and chemotherapy/targeted therapy,
• The volume effect in radiotherapy.

GEC Workshop
Focal therapy for prostate cancer

COURSE AIMS
Brachytherapy is well established as an effective treatment for localised prostate cancer with an acceptable toxicity profile. Current methods aim in general to treat the whole prostate gland. New developments with the application of functional imaging and template biopsies mean that accurate mapping of the distribution of cancer within the prostate is now feasible with considerable accuracy and this has led to a new approach in the management of early prostate cancer using focal ablation of dominant tumour bearing regions within the gland whilst sparing those regions with no evidence of significant tumour and thereby potentially reducing further the toxicity of treatment. The aims of this course are therefore:
• to introduce the concept of focal distribution of cancer in the prostate,
• to review the evidence for imaging modalities to identify significant focal lesions,
• to explore the role of brachytherapy in delivering focal therapy.

WHO SHOULD ATTEND?
All those having an interest in the management of prostate cancer:
• Radiation oncologists
• Urologists
• Radiologists
• Physicists
• RTTs and Specialist nurses

RADIobiology Pre-Meeting Course
Complex tissue interactions in late effects

COURSE AIMS AND LEARNING OBJECTIVES
Research has created complex insights in late normal tissue effects. Multiple molecular pathways, cell and tissue types interact in the development of late normal tissue effects. Insights into these complex interactions have and need to be obtained to reliably predict, prevent and treat late effects. The last decade has known tremendous advances in the field. Therefore this course aims to provide an overview of the latest developments and progress made in the understanding of late normal tissue effects and the potential clinical application of this knowledge.

WHO SHOULD ATTEND?
The course is targeted at radiation oncologists, trainees in radiation oncology, radiation biologists, PhD students and radiation physicists who would like to obtain more insight in the mechanisms and potential clinical application of the latest research in the field of normal tissue damage. In particular attention will be paid to unconventional interactions that may have to be included into the daily practice of treatment planning and post-treatment care.

CONTENT
• Review of the pathology of prostate cancer and its distribution within the gland,
• Physics of prostate brachytherapy and its relevance to focal therapy,
• Overview of main imaging methods, their strengths and weaknesses in defining dominant lesions within the prostate,
• LDR, HDR and PDR brachytherapy techniques for focal therapy,
• Concluding debate: focal vs whole gland therapy for early prostate cancer.

Clinical Course
More information will be available on the ESTRO website
### ISIORT Europe Programme

**Monday, 22 April 2013 • 08:00 - 16:00**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-10:00</td>
<td><strong>IORT BREAST</strong></td>
</tr>
</tbody>
</table>
|               | • **Keynote Lecture:** New Biology models for high single dose  
|               |   C. Herskind (DE)                             |
|               | • Full dose IORT with electrons during breast conserving surgery  
|               |   R. Orecchia (IT)                            |
|               | • Update on TARGIT trial  
|               |   F. Wenz (DE)                                 |
|               | • Update on HIOB - trial hyperfractionated plus intraoperative boost radiotherapy in early stage breast cancer: A prospective multicenter trial  
|               |   F. Sedlmayer (AT)                           |
|               | • IORT Boost: Randomised prospective trial  
|               |   A. Ciabattoni (IT)                          |
| 10:00-10:30   | **Coffee break**                             |
| 10:30-13:00   | **PROFFERED PAPER SESSIONS CLUSTERED BY SUBJECTS**  
|               | Breast, GI/GU, H&N, Sarcoma, Miscellaneous    |
| 13:00-14:45   | **Lunch break**                              |
| 14:45-16:00   | **IMAGING IN IORT - FUTURE DEVELOPMENTS**    |
|               | • Preplanning and navigation: The Madrid experience   |
|               | • Cone beam CT: The Mannheim experience  
|               | • 2D-3D registration: The Salzburg experience  
|               | • Ultrasound

---

### Contouring Workshops

**FALCON** (Fellowship in Anatomic DeLineation and CONtouring) is the multifunctional ESTRO platform for contouring and delineation. Attending a delineation workshop offers the opportunity for individual professionals to validate their contouring practice by comparing their contours with those from experts who propose a clinical case; to learn the indications proposed by the experts that coordinated the workshops; to discuss with other participants, experts and panelists; and, finally, to communicate and use the ESTRO guidelines in order to further integrate these guidelines into daily practice.

FALCON workshops have been organised at ESTRO congresses since 2010 and have been growing steadily in popularity. Therefore, the number of workshops has been increased and we foresee eight workshops in Geneva.

**Structure of the Workshops:**
- Explanation of the contouring software
- Presentation of a clinical case and the delineation exercise
- 30-40 minutes for delineation on site
- Presentation of the delineation guidelines and discussion of the expert’s and participants’ delineations

**Practical Arrangements**

Participants should bring their own laptops. Wifi and wired connection will be available. Participants will be limited to 60 per workshop to keep a strong interactivity in the group.

**Programme**

- **Breast**
  - CHAIR: P. Poortmans (NL) - PANELISTS: A. Biete Sala (ES) and Y. Kirova (FR)
  - Friday, 19 April 2013 from 08:00-10:00
  - Saturday, 20 April 2013 from 08:00-10:00

- **CNS**
  - CHAIR: N. Burnet (UK) - PANELISTS: M. Eble (DE) and U. Ricardi (IT)
  - Friday, 19 April 2013 from 16:00-18:00
  - Saturday, 20 April 2013 from 10:30-12:30
  - Sunday, 21 April 2013 from 08:00-10:00

- **Gynaecology**
  - CHAIR: R. Pötter (AT) - PANELISTS: C. Haie-Meder (FR) and U. Mahantshetty (IN)
  - Friday, 19 April 2013 from 13:30-15:30
  - Monday, 22 April 2013 from 08:00-10:00

- **Normal Tissue**
  - CHAIR and PANELISTS: TBC
  - Friday, 19 April 2013 from 16:00-18:00
  - Tuesday, 23 April 2013 from 08:30-10:30
Awards

*** ESTRO - VARIAN AWARD ***
A prize of 2500 € will be given to a radiotherapy professional for research in the field of radiobiology, radiation physics, clinical radiotherapy or radiation technology.

**Criteria for Eligibility**
1. Candidates should be ESTRO members, having completed the submitted work in the previous year. Submissions should be brought forward by the candidates or their department heads and may be work done as an individual piece of research or as a thesis complete in the field of biological, physical and clinical research.
2. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.
3. Candidates should submit:
   - A curriculum vitae and a list of publications
   - A copy of the abstract on radiation physics or radiation technology which should have been submitted for the 2nd ESTRO Forum (indicating abstract title and submitting author with application)
   - An English summary of their work (max 2 pages)

The candidates should commit themselves to write an original paper in English on (part of) the scientific work carried out. This paper should be based on previously unpublished data and should be written according to the “Instructions to authors” of the Journal “Radiotherapy and Oncology” in which it will be published if accepted.

*** ESTRO - ACCURAY AWARD ***
Two prizes of 2500 € will be given to a radiotherapy professional for research in the field of “High Precision Radiotherapy”. Awardees should be qualified in the field of clinical radiotherapy, radiation physics, radiation technology or radiobiology.

**Criteria for Eligibility**
1. Candidates should be ESTRO members, having completed the submitted work in the previous or current year.
2. Submissions should be brought forward by the candidates and may be work done as an individual piece of research or as a thesis completed in the field of biological, physical or clinical research;
3. Candidates should submit:
   - A curriculum vitae
   - A copy of the abstract on radiation physics or radiation technology which should have been submitted for the 2nd ESTRO Forum (indicating abstract title and submitting author with application)
   - An English summary of their work (max 2 pages)

The candidates should also commit themselves to write an original paper in English on (part of) the scientific work carried out. This paper should be based on previously unpublished data and should be written according to the “Instructions to authors” of the Journal “Radiotherapy and Oncology” in which it will be published if accepted.

*** ESTRO - JACOB FOWLER UNIVERSITY OF WISCONSIN AWARD 2013 ***
A single prize of 1000 € will be given for the best abstract in the field of radiation physics or radiation technology, submitted for the 2nd ESTRO Forum.

**Criteria for Eligibility**
1. Candidates should be ESTRO members.
2. Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.
3. Candidates should submit:
   - A curriculum vitae
   - A letter from their department head stating that the work has been done by the applicant
   - A copy of the abstract on radiation physics or radiation technology which should have been submitted for the 2nd ESTRO Forum (indicating abstract title and submitting author with the application)

The award amounts to 1700 €.

*** ESTRO - NUCLETRON BRACHYTHERAPY AWARD ***
By submitting an abstract for the GEC-ESTRO-ISIORT Europe meeting within the 2nd ESTRO Forum, you are automatically being considered for the “ESTRO-Nucletron Brachytherapy Award”. Abstracts accepted for oral presentation for this meeting will be considered for the award. Since the selection of the winner will be based only on the data provided in the abstract (and not on the presentation) it is advisable that you draft your abstract with extreme care, providing sufficient data for the evaluation by the jury. The award will be given to the most innovative paper submitted for presentation for the GEC-ESTRO-ISIORT Europe meeting. The winning abstract will be selected by the GEC-ESTRO-ISIORT Europe meeting experts. The winner will be notified by email and announced in the 2nd Forum Programme Book and Exhibition Guide.

**Application for the above Listed Awards are to be addressed to:**
ESTRO Office
Av. E. Mounierlaan, 83
1200 Brussels
Belgium
Tel: +32.2.775 93 40 • Fax: +32.2.779 54 94

From 1 November ESTRO is moving to a new address:
Rue Martin V, 40
1200 Brussels
Belgium
E-mail: eralda.azizaj@estro.org
Deadline for submission: 30 November 2012
Awards

*** GEC-ESTRO BEST JUNIOR PRESENTATION SPONSORED BY NUCLETRON ***

Applicants should be in-training members of ESTRO or members younger than 36. If you meet this criterion, please send a copy of the abstract submitted for the GEC-ESTRO-ISiORT Europe meeting and a cover letter from the Head of Department stating that the work has been done by the Junior Applicant to eralda.azizaj@estro.org. This award amounts to 350 € and is sponsored by Nucletron. The winning abstract will be selected by the GEC-ESTRO-ISiORT Europe meeting experts. The winner will be notified by email and announced in the 2nd Forum Programme book and Exhibition Guide. Deadline to apply: 30 November 2012.

*** TRAVEL GRANTS SPONSORED BY NUCLETRON ***

In-training ESTRO members or members younger than 36 who need support to attend the meeting may apply for “Junior Brachytherapy Travel Grants” sponsored by Nucletron. Ten grants of 600 € are available. To apply for a travel grant, please send a motivation letter indicating the reasons why you should be considered for this grant to eralda.azizaj@estro.org. Please indicate your full name, age and ESTRO membership number with your letter. Deadline to apply: 30 November 2012.

*** POSTER AWARDS ***

By submitting an abstract for the 2nd ESTRO Forum, you are automatically being considered for the Best Poster Award. Abstracts accepted for a poster discussion session / poster presentation for the Forum will be considered for the award. The criteria for selection are, in decreasing order of importance, the scientific value of the data, the clarity of their presentation and the visual quality of the poster layout.

Four prizes of 1000 € will be given each to a clinician, physicist, RTT and radiobiologist respectively. Prizes will be handed out at the Poster Reception on Saturday, 20 November 2013.

*** YOUNG SCIENTISTS POSTER AWARDS ***

By submitting an abstract for the 2nd ESTRO Forum, you are automatically being considered for the Best Young Scientists Poster Award. Abstracts accepted for the Young Moving Poster sessions will be considered for the award. The criteria for selection are, in decreasing order of importance, the scientific value of the data, the clarity of their presentation and the visual quality of the poster layout.

Four prizes consisting of a complimentary registration to a future ESTRO Course will be given each to a clinician, physicist, RTT and radiobiologist respectively. Prizes will be handed out at the Young Reception on Monday, 22 April 2013.

Call for Abstracts

GUIDELINES FOR SUBMISSION OF ABSTRACTS

NOTE: ONLY ONE ABSTRACT AS PRESENTING AUTHOR CAN BE SUBMITTED

ABSTRACT SUBMISSION DEADLINE: 7 DECEMBER 2012 (MIDNIGHT CET)

GENERAL INSTRUCTIONS

Abstracts must be submitted on-line on the ESTRO website at: www.estro.org. For questions regarding the on-line submission process, please e-mail events@estro.org.

REGULATIONS

With the submission of the abstract for the 2nd ESTRO Forum, the first (presenting) author:

• Accepts responsibility for the accuracy of the abstract and certifies that all authors are aware of the content before submission

• Accepts to be the contact person for all correspondence related to the abstract and to inform the co-authors about its status

• Accepts to identify any financial interest in products or processes described in the abstract. This includes stock ownership, membership on any advisory boards, commercially sponsored research or any other substantial relationships

• Certifies that the information to be reported is for exclusive presentation in the session to which the abstract will be assigned if accepted and that the information will not be presented as such at any commercially sponsored satellite symposia during the conference

Abstracts must be submitted and presented at the conference in English. The Scientific Committee reserves the right to reject an abstract written in poor English.

Abstracts will be anonymised before review to ensure fairness and eliminate possible bias. Therefore it is strictly forbidden to include the authors’ names or institutions in the body of the abstracts. Submitted abstracts that include such references will be penalised by the Abstract Reviewing Committee.

During the 2nd ESTRO Forum, a Young Scientists Poster Discussion session for authors aged 40 or less will be organised. Please make sure your date of birth is correct in the ESTRO database.

ABSTRACT SUBMISSION (ABSTRACT FORMAT)

• Topic category

Choose the topic category that refers to the main subject of the abstract. Abstracts submitted under the RTT meeting topics are reviewed by radiation technologists and considered for the RTT meeting only. The Scientific Committee reserves the right to re-categorise the abstract.

• Presentation preference

Authors should indicate the presentation preference (oral, poster or no preference). Please note that the final decision on the presentation format rests with the Scientific Committee.

• Keywords

Authors are required to select one keyword from a pre-defined menu. The list of keywords corresponding to each topic category indicated in the table (below) can be a useful guide to determine the most appropriate topic category under which to submit the abstract.

• Title

Abstract titles should be brief and reflect the content of the abstract. The title (maximum 100 characters) is important since it focuses attention (it is the “showcase” for the presentation). Do not use capital letters in the title except for words that are always capitalised and do not use non-standard abbreviations.
**Call for Abstracts**

- **Body of the abstract**
  Abstracts should be structured in such a way as to include (1) Purpose/Objective; (2) Material/methods; (3) Results; (4) Conclusion.

- **The use of standard abbreviations is desirable.**
  A special or unusual abbreviation must be placed (in round brackets) after the first appearance of the word for which it stands.

- **The online abstract submission procedure will not accept abstracts that exceed 2500 characters (body of the abstract, excluding spaces).**

- **Authors may include one data table in the body of the abstract in JPEG format (this is not included in the number of characters).**

- **Authors may include one black and white image in JPEG format.**
  The maximum file size of each image should be 500 KB. The maximum pixel size of the image is 600(w) x 800(h) pixel. Colour illustrations will appear in black and white.

- **Equations can be inserted in the text as images (only JPEG format).**

**Abstract Selection Process**

Abstracts submitted for presentation will be reviewed by an international panel of experts in the field of the subject. Abstract review criteria are based on clarity, supporting data, scientific rigour, potential significance, interest in the topic chosen and innovation or usefulness. Research obviously not yet performed and results not yet obtained will be banned.

Abstracts will be selected for one of the following presentation formats:

- Oral presentation: the abstract is selected for oral presentation at any of the proffered paper sessions.
- Poster discussion session: a limited number of the abstracts will be selected for poster presentation. A chairperson will be selected to discuss the selected posters. Authors who have an abstract accepted for a Poster Discussion session are required to prepare a traditional paper poster and also to upload an electronic version of their poster on the ESTRO system. The electronic version of the poster will be used by the session chairpersons to prepare the discussion for the session.
- Poster presentation: abstracts that have been selected for presentation in a poster format. The posters are grouped by topic and are displayed throughout the meeting. Only a limited number of abstracts will be selected for poster presentation.
- E-poster: abstracts are available for viewing in electronic format in special stations available at the conference venue.

Withdrawal of an abstract: Abstracts submitted for the 2nd ESTRO Forum can be withdrawn until 15 January 2013. (To withdraw your abstract you should send an email to events@estro.org). After this date, withdrawal of abstracts is no longer possible. Abstracts selected for oral / poster discussion / poster presentation should be presented at the meeting. If the first (presenting) author cannot attend the conference, he / she should assign a replacement and inform the ESTRO office of the replacement as soon as possible.

Notification of outcome of abstract submission will be sent by email by end January 2013.

**Abstract Topic Categories**

---

**Topics**

1. CNS and haematology
   - glioma, stereotactic, cranio-spinal RT, paliattion, clinical trial, biological modulation, quality of life, other

2. Head and neck
   - IMRT, chemo-radiation, biological modulation, altered fractionation, clinical trial, HPV, quality of life, other

3. Lung
   - NSCLC, SCLC, chemo-radiation, clinical trial, targeted therapy, extracranial stereotactic, quality of life, other

4. Breast
   - partial breast radiation, normal tissue effect, clinical trial, fractionation study, quality of life, other

5. Gastrointestinal tumours
   - (upper and lower GI)
   - targeted therapy, clinical trial, fractionation, extracranial stereotactic, oligometastatic disease, quality of life, other

6. Genito urinary (Prostate included)
   - clinical trial, image guided therapy, particle therapy, functional imaging, quality of life, other

7. Gynaecological tumours
   - clinical trial, brachytherapy, chemo-radiation, image guided therapy, quality of life, other

8. Sarcoma
   - sarcoma, clinical trial, normal tissue effect, image guided therapy, quality of life, other

9. Paediatrics
   - clinical trial, quality of life, treatment individualisation, particle therapy, late effects, normal tissue effect, quality of life, other

10. Elderley
    - clinical trial, quality of life, treatment individualisation, other

11. Palliation/Supportive care/ Patient support
    - quality of life, hypofractionation, clinical trial, symptom control, other

12. Stereotactic RT
    - hypofractionation, normal tissue effect, image guided therapy, quality of life, other

13. Target and volume definition and imaging
    - image guided therapy, functional/molecular imaging, physical optimisation, biological optimisation, other

14. Health economics
    - cost-benefit, cost-utility, quality assurance, quality systems, radiodinon and radioactive therapy guidelines, other

15. Other tumour sites
    - rare tumours, clinical trials, Phase I/II trials, individualisation of treatment, molecular targeted therapies, genomics/ proteomics, functional imaging, other

---

**Biennial Physics Meeting**

16. Basic dosimetry and phantom and detector developments/ characterisation
    - new detectors, characterisation of detectors, characterisation of phantoms, MC simulation, protons or light ions, dosimetry protocols, other

17. Dose measurements
    - QA treatment units/sources, QA dose calculations, in vivo, pre-treatment verifications, non charged particle equilibrium conditions, neutrons, protons or light ions, small fields, other

18. Dose calculation
    - monitor unit calculation, dose reconstruction, dose mapping, calculation algorithms for TPS, protons or light ions, brachytherapy, QA of calculation algorithms, other

19. Treatment planning and plan comparisons
    - 3DCRT, IMRT, SRS, SRT, 4D planning, brachytherapy, rotational techniques, protons or light ions, comparisons, other
20. Treatment plan optimisation
optimalisation algorithms, robust planning, other

21. Radiobiological modelling
predictions, monitoring, outcome, other

22. Intrafraction motion management
in room imaging/monitoring, motion prediction algorithms, gating, tracking, other

23. Management of interfraction changes
ART, margins, immobilisation and positioning systems, in room imaging/monitoring, correction protocols, geometrical uncertainties, other

24. Imaging: focus on clinical applications
imaging for monitoring treatment outcome, functional imaging, registration strategies, segmentation, 4D imaging for treatment planning, in room imaging, other

25. Imaging: focus on QA and technical aspects
equipment, image registration, dosimetry, geometrical accuracy, image quality, other

26. Implementation of technology, techniques, clinical protocols or trials
treatment techniques (SBRT, IMRT, IGRT, ART, etc), treatment units, imaging equipment, risk and quality management strategies, audits, other

27. Radiation protection
shielding calculations, dose monitoring, accidents, other

28. Professional and educational issues
application of EU directives, education methodology, staffing levels, networks, other

PREVENT MEETING

29. Scoring system on new dose limits
toxicity grades, endpoints, organ at risk, tissue types, tissue functions, scoring system, dose-response, quantitative data, qualitative data, dose limits

30. Modelling and prediction of normal tissue response
modelling, normal tissue, hypothesis testing, dose-response, patient-to-patient variability, treatment planning, predictive assays, training and validation sets

31. (Chemo) radiation-induced cardio / vascular effects
pericarditis, congestive heart failure, coronary artery disease, myocardial infarction, myocardial fibrosis, imaging, delineation of the clinically relevant subregions, chemotherapy, vessel dilation/constriction, telangiectasia, bleeding, ischaemia

32. Effects of biological modifiers on normal tissue tolerance (amelioration / exacerbation)
biological modifiers, growth factors, hypoxia, free radicals, inflammation, macrophages

33. Radiation effects on specific organs / tissue
tissue types, tissue functions, acute effects, late effects, inflammation, fibrosis, atrophy, vascular damage

34. Volume effects on tolerance
dose-volume, guidelines, substructures, functional damage, structural damage, treatment planning, imaging

35. Functional Imaging of normal tissue dose response
anatomical imaging, functional and molecular imaging, quantitative data, biomarkers, endpoints, PET, CT, MRI

36. Stem cell response and therapy
bone marrow transplantation, mesenchymal stem cell, mobilisation of stem cells, tissue-specific stem cells

37. Biological effect of new irradiation modalities
dose rate, hypofractionation, IGRT, SBRT, ART, particle therapy, DNA repair

38. Large cohort studies
ALLEGRO, SEER, ALICCS, EBCTCG, WECARE, St Jude LIFE, epidemiology, dosimetry, late effects, secondary cancer

39. Other

RTT MEETING

40. Patient preparation, patient immobilisation and support aids
patient preparation, immobilisation systems, immobilisation protocols, support aids, respiratory training, markers, patient information, CT simulation protocols, 4D-CT, QA in patient immobilisation, other

41. Treatment planning and dose calculation
plan comparison, treatment planning protocols, OAR doses, IMRT, 3DCRT, rotational therapy, brachytherapy, QA in Treatment planning and dose calculation, other

42. Volume definition, treatment margins, geometric uncertainties and treatment accuracy
delineation of OAR, on board imaging protocols, evaluation of geometrical uncertainties, treatment margins, position verification protocols, position verification procedures, PET-CT, MRI, QA in volume definition, treatment margins and geometric uncertainties, treatment accuracy, other

43. Patient care
psychology, cures, social support, patient associations, palliative care, paediatrics, patient information, toxicity, quality of life, elderly, counseling, side effects, other

44. Education and training
education methodology, training programmes, mobility, other

45. Other

GEC-ESTRO-ISORT MEETING

46. Brachytherapy: Breast Cancer
Other

47. Brachytherapy: Gynaecology
Other

48. Brachytherapy: Head & Neck
Other

49. Brachytherapy: Physics
Other

50. Brachytherapy: Prostate Cancer
Other

51. Brachytherapy: Skin Cancer
Other

52. Brachytherapy: Miscellaneous
Other

53. IORT: Breast Cancer
Other

54. IORT: Gastro Intestinal Cancers
Other

55. IORT: Gynaecology
Other

56. IORT: Head & Neck
Other

57. IORT: Physics and Imaging
Other

58. IORT: Prostate Cancer
Other

59. IORT: Sarcoma
Other

60. IORT: Miscellaneous
Other
## Scientific Programme

**SATURDAY, 20 APRIL 2013**


<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:40</td>
<td>TL: Teaching Lecture / S: Symposium / JS: Joint Symposium / D: Debate / PP: Prolffered Papers / L1: Look Inside / EU: Session on EU Projects</td>
</tr>
</tbody>
</table>
| 08:45 - 10:00 | - redefining the dose distribution  
- redefining the staging  
- the ultimate individualisation  
head and neck radiotherapy in the future:
- Clinical practice - the state of the art  
- Optimation in prostate radiotherapy - where do we put our money?  
- Prostate cancer radiotherapy and biologic targeting: New horizons and opportunities |
| 10:00 - 10:30 | - the optimal use of alternative treatment modalities  
The physics of ablative alternatives to SBRT  
The biology of oligo-metastatic disease  
The role of the UK IGRT lead RTTs  
- Management of lung oligo-metastatic disease  
- Management of brain oligo-metastases  
- Radiotherapy dose painting  
- Functional imaging for radiotherapy dose painting  
- Electrons, the lost particle: Are they still in charge?  
- Head and neck radiotherapy in the future: The ultimate individualisation  
- The role of the UK IGRT lead RTTs  
- The radiobiology of brain oligo-metastases  |
| 10:30 - 11:30 | - the state of the art  
The physics of ablative alternatives to SBRT  
The biology of oligo-metastatic disease  
The role of the UK IGRT lead RTTs  
- Management of lung oligo-metastatic disease  
- Management of brain oligo-metastases  
- Radiotherapy dose painting  
- Functional imaging for radiotherapy dose painting  
- Electrons, the lost particle: Are they still in charge?  
- Head and neck radiotherapy in the future: The ultimate individualisation  
- The role of the UK IGRT lead RTTs  
- The radiobiology of brain oligo-metastases  |
| 11:40 - 12:20 | - redefining the dose distribution  
- redefining the staging  
- Reducing of treatment delivery uncertainties  
- Prostate cancer radiotherapy and biologic targeting: New horizons and opportunities |
| 12:20 - 13:00 | - the optimal use of alternative treatment modalities  
The physics of ablative alternatives to SBRT  
The biology of oligo-metastatic disease  
The role of the UK IGRT lead RTTs  
- Management of lung oligo-metastatic disease  
- Management of brain oligo-metastases  
- Radiotherapy dose painting  
- Functional imaging for radiotherapy dose painting  
- Electrons, the lost particle: Are they still in charge?  
- Head and neck radiotherapy in the future: The ultimate individualisation  
- The role of the UK IGRT lead RTTs  
- The radiobiology of brain oligo-metastases  |
| 13:00 - 14:45 | - redefining the dose distribution  
- Defining the need for systemic treatment  
- BIENNIAL PHYSICS  
The Dose3: Dosimetry, Delivery, Analytics  
- Improveing treatment accuracy  
- Quality of life vs. clinical scoring |
| 14:45 - 16:15 | - redefining the dose distribution  
- Defining the need for systemic treatment  
- BIENNIAL PHYSICS  
The Dose3: Dosimetry, Delivery, Analytics  
- Improveing treatment accuracy  
- Quality of life vs. clinical scoring |
| 16:15 - 16:45 | - redefining the dose distribution  
- Defining the need for systemic treatment  
- BIENNIAL PHYSICS  
The Dose3: Dosimetry, Delivery, Analytics  
- Improveing treatment accuracy  
- Quality of life vs. clinical scoring |
| 16:45 - 18:00 | - redefining the dose distribution  
- Defining the need for systemic treatment  
- BIENNIAL PHYSICS  
The Dose3: Dosimetry, Delivery, Analytics  
- Improveing treatment accuracy  
- Quality of life vs. clinical scoring |
| 18:00 - 19:00 | - redefining the dose distribution  
- Defining the need for systemic treatment  
- BIENNIAL PHYSICS  
The Dose3: Dosimetry, Delivery, Analytics  
- Improveing treatment accuracy  
- Quality of life vs. clinical scoring |

---

## Scientific Programme

**Sunday, 21 April 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 08:40</td>
<td>TL: Biomarkers and the prediction of outcome in breast conserving therapy</td>
</tr>
<tr>
<td>08:45 – 10:00</td>
<td>SS: Breast</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:30 – 11:30</td>
<td>PP: Research challenge from Horizon 2020</td>
</tr>
<tr>
<td>11:40 – 12:10</td>
<td>SS: PRESIDENTIAL SYMPOSIUM</td>
</tr>
<tr>
<td>12:10 – 13:00</td>
<td>SS: HONORARY PHYSICIST AWARD LECTURE</td>
</tr>
<tr>
<td>13:00 – 14:45</td>
<td>13:00-13:45 GEC-ESTRO General Assembly, Satellite Symposium, Poster Viewing</td>
</tr>
<tr>
<td>14:45 – 16:15</td>
<td>SS: Oncology in lung cancer</td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:45 – 18:00</td>
<td>PP: Image-based assessment of the response of normal tissues to radiotherapy</td>
</tr>
<tr>
<td>18:00</td>
<td>General Assembly</td>
</tr>
</tbody>
</table>

**TL:** Teaching Lecture / **SS:** Symposium / **JS:** Joint Symposium / **D:** Debate / **PP:** Proffered Papers / **LI:** Look Inside / **EU:** Session on EU Projects

---

### General Assembly

1. **Biomedical factors influencing the radiotherapy response of breast cancer**
2. **Towards image-based tumour dose response relations: Methods to analyse large CBCT data sets**
3. **Adaptive radiotherapy in practice**
   - Adaptive RT for head and neck cancer: Methodological approaches and clinical outcome
   - Adaptive plans of the day strategies for cervical cancer
   - Adaptive RT for prostate cancer: Methods and clinical outcome
   - A department-wide training programme for image-guided and adaptive RT
4. **Emerging technologies in particle therapy**
   - Proton and ion beam therapy technology developments within the joint CERN-MEDICATRA project
   - Prompt gamma imaging
   - Proton radiography and proton CT for improved range prediction in particle therapy
5. **This house believes that normal structures delimitations should be delegated to RT**
6. **Regenerative therapy**
   - When and how is regenerative therapy an option after radiotherapy
   - Haematopoietic stem cells and radiation
   - Paracrine stimulation
7. **Challenges and pitfalls of image-guided gynaecology and brachytherapy**
8. **ESTRO-CIRSE Percutaneous ablation**
   - How it can complement surgery and radiotherapy
   - Oncology intelligence approaches: small renal tumours: is it time to stop watching them grow?
   - Local treatment of pulmonary tumours
   - Emerging techniques in treating hepatic malignancy
   - Assessing outcomes in local tumour treatment, and the value of multidisciplinary collaboration: Lessons from radiotherapy oncology
Scientific Programme
MONDAY, 22 APRIL 2013

<table>
<thead>
<tr>
<th>TIME</th>
<th>CLINICAL MEETING</th>
<th>INTERDISCIPLINARY MEETING</th>
<th>BIENNAL PHYSICS MEETING</th>
<th>RTT MEETING</th>
<th>YOUNG TRACK</th>
<th>ISORT EUROPE MEETING</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:40</td>
<td>TL Splectore preservation in anal cancer</td>
<td>TL The challenge of biological targeting</td>
<td>TL Risk management</td>
<td>TL Statistical methods for fitting of response/ biologic models to clinical data</td>
<td>TL PET for delineation in radiotherapy: Reliability and opportunities</td>
<td>S IORT breast</td>
</tr>
<tr>
<td>08:45 - 10:00</td>
<td>D Does this house believe that we can avoid surgery in respondent rectal cancer?</td>
<td>S The impact of Omes and Omics, on radiation oncology</td>
<td>S Inaccuracies and near misses in radiotherapy and how to address them</td>
<td>S Advanced methods for target- cty predictive models</td>
<td>S PET for delineation in radiotherapy: Reliability and opportunities</td>
<td>S IORT breast</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td>S Flattening filter free linacs: PPF and new dosimetric challenges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:30</td>
<td>PP</td>
<td>S Future radiotherapy clinical trials: Salt, paprika and molecular signatures and radiography</td>
<td>PP</td>
<td>S Radiation and targeted therapies: Omes-Omics-Optimisation (Pathways-Procedures-Patients)</td>
<td>PP Highlights of proferrred papers by Young ESTRO members</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:20</td>
<td>PP</td>
<td>S Methods for quality management</td>
<td>S The use of Statistical Process Control (SPC) to monitor processes</td>
<td>S Monitoring of quality in radiotherapy using external audits</td>
<td>PP Highlights of proferrred papers by Young ESTRO members</td>
<td></td>
</tr>
<tr>
<td>12:20 - 13:00</td>
<td>PP</td>
<td>S The potential for radiotopes and targeted therapeutics: First generation studies</td>
<td>S Quality management for contemporary and emerging radiotherapy technologies</td>
<td>S Monitoring of quality in radiotherapy using external audits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:45</td>
<td>Lunch, Satellite Symposium, Poster Viewing</td>
<td>S The radiobiology of particle therapy: The molecular biology of particle and tissue interactions</td>
<td>S Preclinical research: Imaging and delivery challenges: Small animal irradiators</td>
<td>S Monitoring of quality in radiotherapy using external audits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45 - 16:15</td>
<td>S Cervical cancer</td>
<td>S Translational aspects of particle radiobiology: Radiobiology of charged particles and the risk of second cancers</td>
<td>S Dose mapping/ accumulation in treatment adaptation and evaluation: Inverse consistency and transitivitiy effects in dose accumulation with DIR</td>
<td>S PET for delineation in radiotherapy: Reliability and opportunities</td>
<td>S The ESTRO Young Task Force</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• New imaging modalities</td>
<td>S Validation of a DIR algorithm: Practical solutions for head and neck, and cervix.</td>
<td>S Phase I/II: PET in dose 3: Dosimetry, Delivery, (re)planning</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• External irradiation: Does IRR reduce complications? What is the optimal dose when lymph nodes are involved?</td>
<td>S Impact of DIR uncertainties on accumulated dose</td>
<td>S Dose mapping/ accumulation in treatment adaptation and evaluation: Inverse consistency and transitivitiy effects in dose accumulation with DIR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Image-guided adaptive brachytherapy: State of the art</td>
<td>S Phase I/II: PET in dose 3: Dosimetry, Delivery, (re)planning</td>
<td>S Validation of a DIR algorithm: Practical solutions for head and neck, and cervix.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>Coffee break</td>
<td>S Phase I/II: PET in dose 3: Dosimetry, Delivery, (re)planning</td>
<td>S PET for delineation in radiotherapy: Reliability and opportunities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45 - 18:00</td>
<td>S Recurrent gliomas/ GBM</td>
<td>S PET for delineation in radiotherapy: Reliability and opportunities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• New molecular markers for prediction and prognosis - IDH, BRAF and complex markers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Retrmination for recurrent gliomas/ GBM: The optimal treatment combination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clinical experience and current evidence (incl. planning studies) for proton therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The level of evidence for proton therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Evidence vs. re-imbursement vs. patient-demand based proton therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clinical experience and evidence for proton therapy of paediatric cancer patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td>Social Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TOOL OF THE DAY
- Clinical practice: The state of the art and new area of organ preservation
<table>
<thead>
<tr>
<th>Time</th>
<th>Clip</th>
<th>Topic</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:10</td>
<td>TL</td>
<td>Clinical audit</td>
<td></td>
</tr>
<tr>
<td>09:15-10:30</td>
<td>S</td>
<td>Esophageal cancer: Is preoperative radiochemotherapy a standard in early stage?</td>
<td>New ICRU reports and how they are changing practice...</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Basic principles of ICRU concepts</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Upcoming ICRU report on bioeffect modelling</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ICRU-GE-CSTRO report on adaptive brachytherapy in cancer of the cervix</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:00-12:15</td>
<td>S</td>
<td>Symposium</td>
<td>Lymphoma: To irradiate or not to irradiate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Role of radiotherapy in Hodgkin lymphoma in the PET-era</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Role of radiotherapy in the treatment of non Hodgkin lymphoma in the Rituximab era</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reducing late radiation effects by devoting better treatments for lymphoma patients</td>
</tr>
<tr>
<td>12:15-12:45</td>
<td>D</td>
<td>D House believes that hypofractionation will save more prostate cancer patients than precise dose delivery</td>
<td></td>
</tr>
</tbody>
</table>
**General Information**

**UPDATED INFORMATION**
Please consult the ESTRO website on a regular basis for updated information.

**CALL FOR ABSTRACTS**
Abstracts must be submitted online through the ESTRO website which hosts an electronic abstract submission form. One abstract as presenting author can be submitted. Deadline for abstract submission is 7 December 2012.

**ONLINE REGISTRATION**
Registration to the conference will be exclusively through our online registration form via the ESTRO website.

**VENUE**
Palexpo
Route François-Peyrot
1218 Grand-Saconnex
Switzerland

**ACCOMMODATION**
To book your accommodation please go to: www.estro-accommodation.switzerland

**FURTHER INFORMATION**
For further information, please do not hesitate to contact:
Valérie Cremades – Industry & Exhibition Coordinator
e-mail: vcremades@estro.org

**OFFICIAL LANGUAGE**
The official language of the congress is English. No simultaneous translation will be provided.

**POSTERS**
Electronic poster stations located in the exhibition hall and in the poster area will allow you to view the virtual displays at your leisure and to correspond with presenters or forward a presentation to a colleague or home office.

**EXHIBITION**
An exhibition featuring equipment and medical publishers will be held in the Exhibition Area. The opening of the exhibition will be on Friday 19 April 2013 at 19.30. The exhibition will remain open from Friday, 19 April to Monday, 22 April. Entrance is free for all registered participants.

**INSURANCE**
The organiser does not accept liability for individual medical, travel or personal insurance. Participants are strongly advised to take out their own personal insurance policies. In case an unforeseen event would force ESTRO to cancel the meeting, the Society will reimburse the participants the registration fee minus 15% for handling charges. ESTRO will not be responsible for the refund of travel and accommodation costs.

**LUNCHEONS AND REFRESHMENTS**
The registration fee for the conference includes coffee breaks to all participants and exhibitors wearing their conference badges. Lunch will be available for purchase in the exhibition area and is not included in the registration fee.

**OPENING CEREMONY & WELCOME RECEPTION**
All participants and company delegates are invited to the official opening ceremony which will be held in the main auditorium on Friday 19 April, 2013 at 18.00. The opening ceremony will be followed by the welcome reception which will take place in the Exhibition area.

**SATellite SYMposia**
Commercial satellite symposia will be held during lunch breaks. The programmes of the symposia will be published in the official Programme Book and on the ESTRO website. For additional information, please do not hesitate to contact:
Valérie Cremades – Industry & Exhibition Coordinator
e-mail: vcremades@estro.org

**SOCIAL ACTIVITIES**
- **Friday, 19 April 2013**
  - All participants and company delegates are invited to the welcome reception which will take place in the exhibition area as of 19:30 on Friday, 19 April.
  - **Saturday, 20 April 2013**
    - All participants and company delegates are invited to the poster reception and poster awards, which will be held in the poster area on Saturday, 20 April 2013 at 18:00.
  - **Monday, 22 April 2013**
    - All participants are invited to the special evening which will take place in an exclusive venue in Geneva. Additional tickets for this event are available at purchase at EUR 80 + VAT per person.
  - **Tuesday, 23 April 2013**
    - A visit to CERN has been arranged at the end of the Congress at an extra cost. The price will include: a packed lunch, transportation and a guided tour of CERN. There is a limit of 150 places and tickets are available on a first come, first served basis. More information on the congress website.

**HOW TO REACH GENEVA**
Palexpo is located next to Geneva’s international airport and near to the airport railway station and is easily accessible by taxi, bus or train.
The airport is served by the public transport network, Unireso. Only one single ticket is required to travel by train, tram, bus or boat in the area France-Vaud-Geneva. The airport railway station has direct access to the check-in and arrival levels. Journey time to the City Centre (Geneva-Cornavin station) takes 6 minutes and trains run approx. every 12 minutes at rush hour.

The No 5 and No 28 urban bus routes operate from Geneva airport (in front of the railway station) and stop at Palexpo. Buses run every 8-15 minutes.

You can pick up a free ticket for public transport from the machine in the baggage collection area at the Arrival level. This Unireso ticket, offered by Genève Aéroport, allows you to use public transport in Geneva free for a period of 80 minutes.

Hotels in Geneva offer free public transport during your entire stay in Geneva.

Taxi fares between airport and city range from about CHF 30.00 to CHF 35.00 and depend on traffic conditions, time of day and number of passengers. Presently, the fare within Geneva, including airport, is the amount shown on the taximeter.
Registration

ONLINE REGISTRATION
Registering through the ESTRO website is simple and will only take a few minutes. The ESTRO website can be consulted at www.estro.org (click “events”, “2nd ESTRO Forum” and then “register online”. Please follow the instructions included on the electronic registration form before submitting your registration and do not send it again by fax or post. Receipt of registration will be acknowledged electronically.

PAYMENT INFORMATION
Payments can be made either by credit card through our secured website or by bank transfer. For all questions concerning registration and payments, please contact: events@estro.org

REGISTRATION FEE
Reduced fees apply when the payment is received before specific deadlines:
• Early registration rate deadline: 12 December 2012
• Late registration rate deadline: 18 March 2013
• Desk registration rate: as of 19 March 2013

Please note that in order to register for this event at the member price, you must renew your membership for 2013.

The registration fee to the conference includes access to the scientific sessions and exhibition area; the programme and abstract books; coffee breaks; the invitation to the opening ceremony, welcome reception and the social evening.

Registration to the 2nd Forum does not give access to the Pre-congress courses and the Contouring workshops. For these separate registrations are required. However, a full registration allows you to attend the ISORT Meeting. If you only wish to attend the ISORT meeting, you must purchase a one day registration for that day.

CONFIRMATION OF REGISTRATION
Upon receipt of your registration form, a confirmation of your registration will be forwarded to you electronically.

CANCELLATION OF REGISTRATION
In case of cancellation, full refund of the registration fee minus handling charges of 15% may be obtained up to 3 months before the meeting. Between 3 months and 1 month before the meeting, the refund will amount to 50% of the fee. No refund will be possible if the cancellation is postmarked after 19 March 2013.

REGISTRATION FEES
Prices are in Euros

Prices DO NOT INCLUDE VAT
8% VAT will be added during the registration process

<table>
<thead>
<tr>
<th>CONGRESS DEADLINES</th>
<th>EARLY 12/12/2012</th>
<th>LATE 18/03/2013</th>
<th>DESK AS OF 19/03/2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 day RTT / in-training member</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>1 day member</td>
<td>300</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>1 day registration non member</td>
<td>415</td>
<td>415</td>
<td>415</td>
</tr>
<tr>
<td>Student *</td>
<td>210</td>
<td>210</td>
<td>210</td>
</tr>
<tr>
<td>In-training member **</td>
<td>300</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>Member</td>
<td>355</td>
<td>540</td>
<td>685</td>
</tr>
<tr>
<td>Non member</td>
<td>600</td>
<td>775</td>
<td>955</td>
</tr>
</tbody>
</table>

Pre-Congress courses
| In-training member / Student | 105 | 155 | 225 |
| Member | 150 | 190 | 245 |
| Non member | 195 | 235 | 290 |

Contouring workshop
| In-training member | 75 | 75 | 75 |
| Member | 100 | 100 | 100 |
| Non member | 200 | 200 | 200 |

* To register as a student you should send your valid student card to events@estro.org BEFORE doing the registration. Institute letters are not accepted.
** Members with speciality RTT may register at the in-training fee.
**Accommodation**

**TO BOOK YOUR ACCOMMODATION PLEASE GO TO:** [WWW.ESTRO-EVENTS.ORG](http://WWW.ESTRO-EVENTS.ORG) AND CLICK ON 2ND ESTRO FORUM/ACCOMMODATION

The official accommodation agent for the 2nd ESTRO Forum is:

**kuoni destination management**

Geneva Business Centre / Avenue des Margines 12 / CH-1213 Petit-Lancy / Switzerland

Phone: +41 58 702 62 97 • Fax: +41 58 702 64 52 • E-mail: estro2013@ch.kuoni.com

---

### 5* HOTELS

<table>
<thead>
<tr>
<th>HOTEL</th>
<th>SINGLE ROOM</th>
<th>DOUBLE ROOM</th>
<th>DISTANCE TO CONGRESS VENUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>InterContinental 5*</td>
<td>CHF 424.75</td>
<td>CHF 474.50</td>
<td>10 min</td>
</tr>
<tr>
<td>Novotel Geneva Centre 5*</td>
<td>CHF 330.00</td>
<td>CHF 360.00</td>
<td>15 min</td>
</tr>
</tbody>
</table>

### 4* HOTELS

<table>
<thead>
<tr>
<th>HOTEL</th>
<th>SINGLE ROOM</th>
<th>DOUBLE ROOM</th>
<th>DISTANCE TO CONGRESS VENUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auteuil Nanotel 4*</td>
<td>CHF 342.00</td>
<td>CHF 374.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Crowne Plaza 4*</td>
<td>CHF 334.00</td>
<td>CHF 376.00</td>
<td>15 min</td>
</tr>
<tr>
<td>East West 4*</td>
<td>CHF 404.00</td>
<td>CHF 472.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Novotel Geneva Centre 4*</td>
<td>CHF 364.00</td>
<td>CHF 385.00</td>
<td>15 min</td>
</tr>
<tr>
<td>The New Red 4*</td>
<td>CHF 348.00</td>
<td>CHF 376.00</td>
<td>20 min</td>
</tr>
<tr>
<td>NH General Airport 4*</td>
<td>CHF 324.00</td>
<td>CHF 363.00</td>
<td>15 min</td>
</tr>
<tr>
<td>NH Blue 4*</td>
<td>CHF 320.00</td>
<td>CHF 361.00</td>
<td>20 min</td>
</tr>
<tr>
<td>Novotel Geneve Centre 4*</td>
<td>CHF 374.00</td>
<td>CHF 408.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Novotel Geneva Centre 4*</td>
<td>CHF 364.00</td>
<td>CHF 395.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Crowne Plaza 4*</td>
<td>CHF 334.00</td>
<td>CHF 378.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Royal 4*</td>
<td>CHF 364.00</td>
<td>CHF 398.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Starling 4*</td>
<td>CHF 299.00</td>
<td>CHF 318.00</td>
<td>Walking distance (*)</td>
</tr>
</tbody>
</table>

### 3* HOTELS

<table>
<thead>
<tr>
<th>HOTEL</th>
<th>SINGLE ROOM</th>
<th>DOUBLE ROOM</th>
<th>DISTANCE TO CONGRESS VENUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bel Air 3*</td>
<td>CHF 222.30</td>
<td>CHF 255.60</td>
<td>15 min</td>
</tr>
<tr>
<td>Astoria 3*</td>
<td>CHF 243.60</td>
<td>CHF 291.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Bernina 3*</td>
<td>CHF 170.00</td>
<td>CHF 240.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Best Western Chamonix 3*</td>
<td>CHF 188.00</td>
<td>CHF 221.00</td>
<td>15 min</td>
</tr>
<tr>
<td>La Colombe 3*</td>
<td>CHF 202.30</td>
<td>CHF 266.60</td>
<td>Walking distance</td>
</tr>
<tr>
<td>Cervinia 3*</td>
<td>CHF 244.00</td>
<td>CHF 288.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Design Hotel Fv 3*</td>
<td>CHF 255.00</td>
<td>CHF 304.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Drake 3*</td>
<td>CHF 193.30</td>
<td>CHF 246.60</td>
<td>15 min</td>
</tr>
<tr>
<td>Expressions 3*</td>
<td>CHF 261.30</td>
<td>CHF 306.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Express By Holiday Inn 3*</td>
<td>CHF 220.00</td>
<td>CHF 220.00</td>
<td>5 min (*)</td>
</tr>
<tr>
<td>Jade Manotel 3*</td>
<td>CHF 281.10</td>
<td>CHF 302.60</td>
<td>15 min</td>
</tr>
<tr>
<td>Impression 3*</td>
<td>CHF 228.30</td>
<td>CHF 292.60</td>
<td>20 min</td>
</tr>
<tr>
<td>K Hospice 3*</td>
<td>CHF 200.00</td>
<td>CHF 225.00</td>
<td>15 min</td>
</tr>
<tr>
<td>N'Vy (ex. Epsom) 3*</td>
<td>CHF 281.30</td>
<td>CHF 302.60</td>
<td>15 min</td>
</tr>
<tr>
<td>Royal 3*</td>
<td>CHF 255.00</td>
<td>CHF 298.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Savoy 3*</td>
<td>CHF 230.00</td>
<td>CHF 245.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Strasbourg 3*</td>
<td>CHF 222.00</td>
<td>CHF 262.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Suisse 3*</td>
<td>CHF 223.00</td>
<td>CHF 262.00</td>
<td>15 min</td>
</tr>
<tr>
<td>Central 2*</td>
<td>CHF 138.00</td>
<td>CHF 171.00</td>
<td>30 min</td>
</tr>
<tr>
<td>Eco 2*</td>
<td>CHF 162.00</td>
<td>CHF 185.00</td>
<td>15 min</td>
</tr>
</tbody>
</table>

(*) Hotel is offering shuttle services from/to airport

---

**ALL HOTEL RATES ARE IN SWISS FRANCS (CHF), PER ROOM, PER NIGHT, INCLUDING BREAKFAST, SERVICE CHARGES, VAT AND CITY TAX.**

In General rooms are available April 19-23, 2013. Additional nights are only available upon request and are subject to availability. Rooms will be assigned on a "first come, first served" basis. A deposit of one night charge per reserved room is required to secure your hotel reservation. The first night deposit or the full pre-payment must be received on KUONI bank Account no later than 14 days after booking.

**PLEASE NOTE THE FOLLOWING BOOKING & CANCELLATION POLICY WHICH WILL APPLY TO ALL INDIVIDUAL BOOKINGS:**

- **5 & 4* HOTELS**
  - Up to 60 days prior to arrival: 100% refund less bank charges
  - From 60 to 30 days prior to arrival: 1 night cancellation fee
  - Less than 30 days prior to arrival and No-Shows: no refund

- **2* & 3* HOTELS**
  - Up to 30 days prior to arrival: 100% refund less bank charges
  - From 30 to 7 days prior to arrival: 1 night cancellation fee
  - Less than 7 days prior to arrival and No-Shows: no refund

All cancellations and changes are to be addressed to KUONI in writing. Please note, that additional nights are strictly subject to availability.

In case of no-show the hotel will automatically release the reservation. Full reservation stay will be charged after the first day of no show.

**Early Departure Fee:** Guests will be charged in full for checking out prior to the departure date confirmed.

All refunds will be processed after the 2nd ESTRO Forum AND will be paid in CHF. Participants unable to attend may transfer their booking to another person.
MEMBERSHIP

GET THE NEW ESTRO MEMBERSHIP AND PAY LESS FOR MORE SERVICES!

ESTRO has made considerable efforts to improve the structure of its individual membership programme and is pleased to introduce several new membership categories. These have all been designed to provide the society’s members with even more relevant and cutting-edge professional tools and benefits. Discover the new categories and related membership benefits here and choose the one that is best tailored to suit your needs!

- **Active member at 95 €**
  This category entitles you to the most complete range of services that the society has on offer. ESTRO is developing a wide range of new online services which will be functional as of January 2013: through our new search engine you will be able to access a comprehensive e-library containing documents such as the Green Journal and conference abstracts, web casts, posters, free access to FALCON (our delineation tool), newsletter, etc…

- **Supporting Membership**
  This category is reserved for individuals who are strongly committed to the Society and who want to take an extra step to help ESTRO develop further by paying a higher membership fee. The additional income generated by these big-hearted members will be used to create a solidarity fund. The fund will be available to sponsor the membership fee of less fortunate individuals, finance support grants for ESTRO events, and help to ensure that RO professionals from economically challenged countries are also able to participate in our scientific arena.

RTBs will now belong to the ‘Active Member’, ‘In Training Member’ or ‘Affiliate Member’ categories which have no distinction of disciplines.

The previous ‘Electronic membership’ has been replaced by the ‘Affiliate Membership’, although the advantages have been enhanced.

The various categories of membership and their benefits are summarised in the table below. And don’t forget that you can register for the 2013 conferences and teaching courses at the discounted rate as soon as you have your 2013 membership!

**Membership renewal is only possible online**: [www.estro.org](http://www.estro.org)

**Two entirely new membership categories are being launched for 2013:**

- **ESTRO Institutional Membership**
  Your institute can buy several individual memberships and take advantage of additional benefits such as registration packages for online workshops, a dedicated corner in the Newsletter, the opportunity to disseminate standards/guidelines within the organisation and much more.

- **Supporting Membership**
  All professionals in the field of RO. The extra fee is for supporting the ESTRO Foundation activities through a Solidarity Fund: to sponsor individual or institutional membership and grants for ESTRO events.

Together with the ‘Active member’ or ‘Affiliate member’ categories which have no distinction of disciplines, the ‘In Training Member’ or ‘Honorary Member’ categories have all been designed to provide the structure of its individual membership programme and much more.

**Definition**

<table>
<thead>
<tr>
<th>Full Membership</th>
<th>Associate Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Supporting Ambassador</strong></td>
<td>All professionals in the field of cancer care and/or cancer research – and related areas – in a non-commercial environment</td>
</tr>
<tr>
<td><strong>Active Members</strong></td>
<td>All European professionals in the field of RO are eligible for this membership. The minimum of 5 years ago and in training post</td>
</tr>
<tr>
<td><strong>Honorary Members</strong></td>
<td>Professors having made a significant contribution to the advancement of the purpose of ESTRO, to be identified by the Nominating Council of ESTRO</td>
</tr>
<tr>
<td><strong>Dual Members</strong></td>
<td>Individual members from outside membership agreements. Requirements are signed on a case-to-case basis between the ESTRO National Society and/or individual who have ratified in the field of Radiation Oncology</td>
</tr>
<tr>
<td><strong>Affiliate Members</strong></td>
<td>Individual members who do not wish to become active members and/or individuals who have made significant contributions in the field of Radiation Oncology.</td>
</tr>
</tbody>
</table>

**Benefits**

- **Online access to all educational material**
  - Contribution to ESTRO ambassadors/Solidarity fund
  - Eligible for fellow
  - Voting rights
  - Eligible for President and Board of Directors
  - Eligible for Councils and Standing Committees
  - Eligible for Working Groups and Task Force Groups
  - Eligible for Faculties
  - Eligible for participating in ESTRO’s governance activities

- **Access FALCON cases**
  - basic + extended cases
  - basic
  - basic + free

- **Webcast Library**
  - immediate after 6 months
  - after 6 months

- **Access to Membership directory**
  - x
  - x

- **Open access to “Members area” on ESTRO website**
  - read and upload
  - read
  - read
  - read
  - read
  - read

- **Access to Job advertisements**
  - x
  - x
  - x
  - x
  - x

- **Eligible for Awards**
  - European Journal of Cancer (reduced subscription)
  - Eligible for Grants
  - Reduced fee for attending ESTRO and Joint Courses
  - Reduced fee for attending ESTRO and Joint Courses

- **Green Journal**
  - x
  - x
  - x
  - x
  - x

- **Special access to ESTRO Handbooks**
  - x
  - x
  - x
  - x

- **Special access to ESTRO publications and handbooks**
  - x
  - x
  - x
  - x

**FEES**

<table>
<thead>
<tr>
<th>Corporate</th>
<th>€ 240.00</th>
<th>€ 195.00</th>
<th>€ 75.00</th>
<th>€ 55.00</th>
<th>€ 55.00</th>
</tr>
</thead>
</table>
...twice the leaves at twice the speed

With Agility™, it’s reality.

As the ultimate device for advancing modern radiotherapy, Elekta’s Agility MLC precisely sculpts radiation with 160 high-resolution leaves across a 40 cm x 40 cm field. Capable of managing the broadest spectrum of therapies, Agility also boasts ultra-fast leaf movements with extraordinarily low leakage to maximize the potential for advanced techniques such as SRS, SRT and VMAT.

Agility is not licensed for sale in all markets. Please contact your local Elekta representative for details.